Table 3.
Associations Between Warfarin Use and Outcomesa
| Outcome | Unadjusted HR (95% CI) | Weighted HR (95% CI) | Weighted and Adjusted HR (95% CI)b |
|---|---|---|---|
| Mortality | |||
| 30 days | 0.99 (0.66–1.48) | 0.96 (0.60–1.53) | 0.96 (0.61–1.52) |
| 1 year | 0.73 (0.61–0.86) | 0.76 (0.63–0.92) | 0.77 (0.64–0.92) |
| Thromboembolic events | |||
| 30 days | —c | —c | —c |
| 1 year | 0.89 (0.58–1.39) | 0.92 (0.60–1.41) | 0.93 (0.60–1.43) |
| New myocardial infarction | |||
| 30 days | —c | —c | —c |
| 1 year | 0.91 (0.51–1.59) | 1.18 (0.62–2.25) | 1.40 (0.72–2.72) |
| Bleeding events | |||
| 30 days | —c | —c | —c |
| 1 year | 0.90 (0.58–1.40) | 1.13 (0.69–1.85) | 1.18 (0.71–1.96) |
Abbreviations: CI, confidence interval; HR, hazard ratio.
a
Warfarin use defined as documentation of a warfarin prescription at the time of discharge in the Acute Decompensated Heart Failure National Registry.
b
Cox proportional hazards model includes adjustment for prescription of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, aspirin, β‐blocker, diuretic, clopidogrel, and lipid‐lowering medication at discharge.
c
Data suppressed because of insufficient observations.